TL1A
- Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies
- A Phase 1 open-label study in Australia is underway to evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers
- Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025
Key Data
Preclinical data indicate a best-in-class dosing interval for patient convenience and efficacy compared to the first and second-generation anti-TL1A candidates.
High Potency
Equal or more potent than competitors based on in vitro assays. Potency in line with first line anti-TL1A mAbs demonstrated by neutralization of TF-1 cells.
Low Immunogenicity Risk
Low immunogenicity risk predicted by pre-clinical models.
Industry Leading Half-Life
Q9-12M modeled dosing frequency to reduce patient burden. PBPK modeling suggesting industry leading 100+ day predicted half-life.
Differentiated Product Profile
BB-TL1A-VIAL-HLE is potentially a best-in-class anti-TL1A mAb with an extended half-life to support Q9-12M dosing, powered by Vial’s HLE platform. The program is also applicable to MASH, Atopic Dermatitis, SSc-ILD, Rheumatoid Arthritis, Hidradenitis Suppurativa, among others.
